Satellos Bioscience Inc Stock Price, News & Analysis

Satellos Bioscience (TSX:MSCL, OTCQB:MSCLF), a biotech company focused on developing small molecule therapeutics for muscle diseases, announces its participation in Oppenheimer's Movers in Rare Disease Summit in New York City on December 12, 2024. Frank Gleeson, Co-founder and CEO, will participate in a fireside chat titled 'Polypharmacy in DMD and Neuromuscular Disease' at 9:50AM ET. The management team will also be available for one-on-one meetings with registered summit attendees.

Satellos Bioscience (TSX:MSCL, OTCQB:MSCLF) announces participation in a live investor webinar focused on Duchenne muscular dystrophy (DMD) on December 4, 2024, at 2:00 pm ET. The webinar will feature key opinion leaders discussing three main topics: new treatment approaches for DMD, patient navigation of clinical trials, and Satellos' novel small molecule approach focusing on muscle regeneration.

Featured speakers include Elijah Stacy, a DMD patient advocate and Founder of Destroy Duchenne, Dr. Michael Rudnicki, Scientific Founder of Satellos and Director of Regenerative Medicine at Ottawa Hospital Research Institute, and Dr. Jordan Dubow, Satellos' CMO. The event will include a Q&A session and is free to attend.

Satellos Bioscience (TSX: MSCL, OTCQB: MSCLF) has appointed Stephanie Brown to its Board of Directors. Brown brings over 30 years of biopharma industry experience, with expertise in product commercialization and organizational transformation. She has held executive positions at major pharmaceutical companies including Santhera, Ipsen, Merck, Genentech, Biogen, Takeda, and Novartis, where she managed high-value product portfolios and led successful product launches. Her experience includes the commercialization of Aimovig, a breakthrough migraine prevention therapy. Currently, she serves on the Board of Directors for Resilia, Inc.

Satellos Bioscience reported Q3 2024 financial results and clinical updates for its DMD treatment SAT-3247. The company completed enrollment in the first three single-ascending dose cohorts with no safety concerns and initiated the first multiple-ascending-dose cohort. Key financial highlights include cash balance of $23.4M (down from $39.6M in December 2023) and Q3 net loss of $9.0M ($0.08/share) compared to $3.6M ($0.03/share) in Q3 2023. R&D expenses increased to $3.3M from $2.7M year-over-year. The company presented promising canine trial data showing improved muscle strength reaching near normal levels.

Satellos Bioscience (TSX: MSCL) (OTCQB: MSCLF), a biotech company focused on developing small molecule therapeutics for muscle diseases, has announced its participation in three major investor conferences in November 2024. The company will participate in a fireside chat at the Guggenheim Securities Healthcare Innovation Conference on November 13, deliver a presentation at the Stifel Healthcare Conference on November 18, and conduct one-on-one meetings at the Jefferies London Healthcare Conference from November 19-21. Both the fireside chat and presentation will be available via webcast on the company's website with replay options.

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) announced promising results from a pilot study of SAT-3247, their oral small molecule treatment for Duchenne muscular dystrophy (DMD), in a canine model. After four months of daily treatment:

- Muscle function returned to near-normal levels compared to healthy animals
- Increased Regenerative Index (RI) in diaphragm, calf, and quadriceps muscles
- No adverse events or significant changes in hematology or clinical chemistry
- Trends towards lower creatine kinase levels, potentially indicating disease modification

The data will be presented at the 29th Annual Congress of the World Muscle Society in October 2024. Satellos believes these results are groundbreaking, especially given the severity of the canine DMD model compared to mouse models.

Satellos Bioscience Inc. (TSX: MSCL) (OTCQB: MSCLF) has initiated a Phase 1 clinical study for SAT-3247, a novel oral small molecule drug targeting AAK1. The drug is designed to regenerate skeletal muscle in Duchenne muscular dystrophy (DMD) and other muscle degenerative conditions. The study comprises two components:

1. A trial with 72 healthy volunteers to assess safety and pharmacokinetics, including single-ascending dose (SAD), multiple-ascending dose (MAD), and food effect cohorts.

2. A 28-day, open-label, single dose cohort with 10 adult DMD patients, expected to begin in late Q4 2024.

Initial safety and pharmacokinetic data are anticipated in Q4 2024, with the DMD patient component starting in Q1 2025.

Satellos Bioscience Inc. (TSX: MSCL) (OTCQB: MSCLF), a biotech company developing new small molecule therapeutics for muscle diseases, has announced its participation in two upcoming investor conferences in New York City. CEO Frank Gleeson and CFO Elizabeth Williams will represent the company at these events:

1. H.C. Wainwright 26th Annual Global Investment Conference: Fireside chat on Wednesday, September 11th at 8:00 a.m. ET

2. Cantor 2024 Global Healthcare Conference: Fireside chat on Thursday, September 19th at 9:45 a.m. ET

Both presentations will be available via live webcast on the company's website, with replays accessible afterwards.

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) has announced the acceptance of a regulatory filing to commence a Phase 1 clinical trial for SAT-3247, a potential oral treatment for Duchenne muscular dystrophy (DMD). The trial, expected to begin dosing in Q3 2024, will be conducted in Australia under the Therapeutic Goods Administration's Clinical Trial Notification scheme.

The study will consist of two parts: 72 healthy volunteers will participate in single-ascending dose, multiple-ascending dose, and food effect cohorts to assess safety and pharmacokinetics. Additionally, 10 adult DMD patients will be enrolled in a 28-day, open-label cohort to compare data and explore pharmacodynamic markers. This milestone marks Satellos' advancement into clinical development with a novel small molecule approach aimed at restoring muscle regeneration and repair in DMD patients.